Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | DRD1 | P21728 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628834 | 0.86 | ABCB11 (0.44) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL1269320 | 0.86 | DRD1 (0.47) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL954553 | 0.86 | DRD1 (0.47) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Bromide SCHEMBL2087060 | 0.85 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077705 | 0.85 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077710 | 0.85 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL5024496 | 0.84 | ABCB11 (0.42) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6615615 | 0.84 | DRD1 (0.45) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL5028770 | 0.83 | ABCB11 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL6208238 | 0.83 | ABCB11 (0.42) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | claimed |
| CN-111665303-B | Kit for detecting anti-platelet drugs in plasma by ultra-high performance liquid chromatography tandem mass spectrometry technology | 南京品生医疗科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-114938659-A | Cardiovascular disease onset risk assessment marker based on metabonomics data and application | 中国医学科学院阜外医院 | 2022-08-23 | — | — | CN | claimed |
| CN-111812223-B | Method for detecting antiplatelet drugs in plasma by ultra-high performance liquid chromatography tandem mass spectrometry technology | 南京品生医学检验实验室有限公司 | 2022-08-16 | — | — | CN | claimed |
| WO-2022166935-A1 | CARDIOVASCULAR DISEASE INCIDENCE RISK ASSESSMENT MARKER BASED ON METABOLOMIC DATA AND APPLICATION THEREOF | 中国医学科学院阜外医院 | 2022-08-11 | — | — | WO | claimed |
| CN-112509704-A | Acute coronary syndrome early warning method and device based on metabonomics data | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | claimed |
| CN-112509695-A | Acute coronary syndrome early warning method and device for stable coronary heart disease patient | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | claimed |
| CN-112505199-A | Stable coronary heart disease early warning method and device based on metabonomics data | 中国医学科学院阜外医院 | 2021-03-16 | — | — | CN | claimed |
| CN-111812223-A | Method for detecting antiplatelet drugs in plasma by ultra-high performance liquid chromatography tandem mass spectrometry technology | 南京品生医学检验实验室有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-111665303-A | Kit for detecting antiplatelet drugs in plasma by ultra-high performance liquid chromatography tandem mass spectrometry technology | 南京品生医疗科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | disclosed |
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | disclosed |
| US-20250066381-A1 | ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS | MOLECULES & MATERIALS (KR) | 2025-02-27 | — | — | US | disclosed |
| CN-114286823-B | Optically active 2-hydroxy tetrahydrothiophene pyridine derivative and preparation method and application thereof | 天地恒一制药股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116744921-A | Optically active 2-hydroxy tetrahydrothiophene pyridine derivative and preparation method and application thereof | 天地恒一制药股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090214602-A1 | ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ENTERICALLY COATED ACID INHIBITOR | KG ACQUISITION LLC | 2009-08-27 | — | — | US | disclosed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966219-A1 | PROCESS FOR THE PREPARATION OF S-(+)-CLOPIDOGREL BY OPTICAL RESOLUTION | SK CHEMICALS CO., LTD. (KR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007074995-A1 | PROCESS FOR THE PREPARATION OF S-(+)-CLOPIDOGREL BY OPTICAL RESOLUTION | SK CHEMICALS CO., LTD. (KR) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066381-A1 | ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS | TBXAS1, TASP1, GART | ABCB11 355/4885CYP2C19 217/4885DRD1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.